Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates Elicio Therapeutics (Nasdaq: ELTX) reported 2025 results and clinical updates on March 12, 2026. The company expects an event-driven primary DFS analysis in 1H 2026 from the randomized Phase 2 AMPLIFY-7P trial in resected mKRAS PDAC and remains blinded to efficacy outcomes.Notable 2025 financials: R&D $24.9M, G&A $12.8M, net loss $39.6M, and $18.6M cash with runway into Q3 2026; antigen spreading and T-cell durability were reported in December 2025.

#ELTX Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...

#ELTX Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P

#ELTX Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...

Trade Alert, Wednesday November 5, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend, Av Dir Indx, Wed Nov 5th - #SNDL #PNRG #NNOX #MCRB #LCUT #KRNT #HEPS #CPIX #DEFT #ELTX #GSM #VYGR #BAND #ABEO #BBAI #SI #PRG #ONTF #MVO #MNTN #HPP #FPI #CABO #TIL - More: crystalequityresearch.com/trade-alert-... - #smallcap

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial Elicio Therapeutics (Nasdaq: ELTX) reported preliminary Phase 2 AMPLIFY-7P results showing that ELI-002 7P induced mKRAS-specific T cell responses across diverse HLA backgrounds.Among 89 patients, 1,132 unique HLA types were identified out of 1,398 total HLA types assessed, and 99% (88/89) of patients assessed for HLA background mounted mKRAS-specific T cell responses after treatment. The company said these findings suggest mKRAS antigens can be presented across many HLA alleles, implying potential applicability to a broad population of pancreatic ductal adenocarcinoma (PDAC) patients.Results are described as preliminary and come from an ongoing Phase 2 study; additional data and follow-up were not provided.

#ELTX Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

www.stocktitan.net/news/ELTX/elicio-therape...

145-fold Immune Response Boost: Elicio's Cancer Vaccine Shows Remarkable 99% Success Rate in Phase 2 Study Biotech's ELI-002 7P vaccine achieved mKRAS-specific T cell responses in 89 of 90 patients, with 145.3x average increase. Final survival data expected Q4 2025. Phase 2 includes both MRD+ and MRD- patients.

#ELTX Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio (ELTX) Q2 Loss Beats Estimates | The Motley Fool

#ELTX #952ef8ce-4657-4230-a097-23868341355c #data-news

Origin | Interest | Match

Positive Trial Results: Elicio's Pancreatic Cancer Vaccine Shows Promise, Final Data Coming Q4 2025 IDMC backs ELI-002 Phase 2 trial in pancreatic cancer. $10M financing extends runway to 2026. Key survival data expected Q4 2025. Get full details.

#ELTX Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis Elicio Therapeutics (NASDAQ:ELTX) announced that the Independent Data Monitoring Committee (IDMC) has recommended continuing the Phase 2 AMPLIFY-7P study of ELI-002 7P for pancreatic cancer without modifications. The trial, involving 144 patients across 24 U.S. sites, evaluates ELI-002 7P's effectiveness against standard of care in improving disease-free survival (DFS) for pancreatic ductal adenocarcinoma (PDAC) patients.The IDMC's positive recommendation suggests preliminary efficacy signals and confirms a favorable safety profile. The final DFS analysis is expected in Q4 2025. Notably, Elicio has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026.

#ELTX Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Lands $10M Funding to Advance Revolutionary Cancer Vaccine Through Critical Trial Phase New financing extends operations beyond key Phase 2 cancer vaccine trial milestone. Breakthrough KRAS-targeting therapy shows promise in pancreatic cancer. See trial timeline.

#ELTX Elicio Therapeutics Secures $10 Million in Financing

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Elicio Therapeutics (NASDAQ: ELTX) reported its Q1 2025 financial results and provided corporate updates. The company is advancing toward a crucial Phase 2 AMPLIFY-7P interim analysis expected in Q3 2025, focusing on disease-free survival in pancreatic cancer treatment. Key financial highlights include: R&D expenses of $7.8M (up from $7.6M in Q1 2024), G&A expenses of $3.0M (up from $2.7M), and a net loss of $11.2M ($0.87 per share). The company's cash position of $18.4M is expected to support operations into Q4 2025.Notable developments include FDA alignment on key Phase 3 study design elements for ELI-002, appointment of Preetam Shah as Chief Strategy and Financial Officer, and a $10M registered direct offering. ELI-002 represents a potential breakthrough in treating mKRAS-driven tumors, particularly for pancreatic cancer patients with a 13% 5-year survival rate.

#ELTX Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data Phase 1a shows 28.9-month survival data as Phase 2 enrollment completes. $10M funding extends operations through Q4 2025. FDA aligns on Phase 3 design.

#ELTX Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of moving average convergence divergence signal, Mon Feb 10th - #XPEL #WPRT #UFPT #TBPH #SEVN #RZLT #PCRX #OCCI #MERC #JRVR #HRTX #ELTX #DCTH #CCSI #BDTX #UNFI #SMWB #GGT #DHT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Elicio Therapeutics Raises Fresh Capital: $10M Strategic Funding Deal Includes Bonus Warrants Biotech firm Elicio Therapeutics announces $7.925 per share offering with matching warrants, aiming to strengthen working capital. Deal includes 1.26M shares plus 5-year warrants.

#ELTX Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy FDA aligns with Elicio's Phase 3 design for ELI-002 in KRAS-mutated pancreatic cancer. Phase 2 study fully enrolled with interim results expected in H1 2025.

#ELTX Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio's Cancer Vaccine Shows Promising 28.9-Month Survival in Phase 1 KRAS Trial Data Elicio's ELI-002 cancer vaccine demonstrates strong survival outcomes in KRAS-mutant tumors, with significant T-cell response correlation and favorable safety profile in Phase 1 data.

#ELTX Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

#news #StockMarket #investing

www.stocktitan.net/news/ELTX/elicio-therape...

Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment | ELTX Stock News Elicio Therapeutics achieves rapid enrollment of 135 patients in Phase 2 AMPLIFY-7P study for pancreatic cancer treatment ELI-002 7P, with interim results expected in H1 2025.

#ELTX Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

#StockMarket #news #stocks

www.stocktitan.net/news/ELTX/elicio-therape...

#ELTX Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/ELTX/elicio-therape...